Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound)

TheMotleyFool

0 0

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound): https://g.foolcdn.com/editorial/images/790189/gettyimages-2152342460.jpg

Eli Lilly (NYSE: LLY) might just be the hottest pharmaceutical company on the planet right now. The company is the developer of a number of blockbuster drugs including Verzenio, Trulicity, and Taltz.

Of course, I'd be remiss to not include the company's latest hits in weight loss. Lilly's diabetes and obesity care medications, Mounjaro and Zepbound, are currently fueling a new wave of growth for the pharma leader and I don't see that slowing anytime soon.

But what if I told you that there's an entirely other reason to love Eli Lilly stock besides its highly successful medicine portfolio?

Source Fool.com

Like: 0

LLY

Share